24 results about "Epithelial tissue" patented technology

A method and system to make a modular microfluidic device in a miniaturized form for cell culture, co-culture, and organ-on-a-microfluidic device as in-vitro model of human organs within compartmentalized 3D structures is described. The modular microfluidic device enables co-culturing of heterogeneous cell assemblies that are adjacent or sequentially connected to promote enhanced cell-cell interaction. In vivo-like flow into and / or from one cell growth chamber to adjacent cell growth chamber is maintained by micro-engineered porous barriers i.e., porous walls and membranes. These porous barriers provide a tool for mimicking the paracrine exchange between cells in the human body. The system comprises of a set of microelectrodes for real-time and long-term monitoring and quantitative measurement of the impact of stimuli on the epithelial tissue permeability. The modular microfluidic system provides a platform technology for bio-fabrication of variety of miniaturized in-vitro models for mimicking the structure and function of single and multi-organ models.

A robust nasal organoid culture system and fully characterized 2D and 3D in vitro produced organoids are provided, as well as methods of using the organoids. The nasal organoids comprise a population of differentiated nasal epithelial cells having cellular heterogeneity and molecular markers similar to mature nasal epithelial tissue. Improved methods for producing two-dimensional and three-dimensional nasal organoids are also provided. These methods generally require a two-phase culture system, i.e., amplification and differentiation culture. The provided nasal organoids are suitable for reproducing nasal tissue complexity, for mimicking respiratory diseases, studying barrier function and drug delivery, high throughput drug screening, and assessing the effects of pathogens and environmental toxins on nasal respiratory epithelium.

The invention belongs to the technical field of medical materials, and discloses an external gel material for treating oral mucositis and a preparation method of the external gel material. The gel is temperature-sensitive slow-release antibacterial gel, adopts safe components, has a temperature-sensitive characteristic, is in a sol state in a low-temperature state, is convenient to smear, can be converted into a gel state when the temperature is close to the body temperature of a human body, can be tightly attached to an oral mucosa, is good in adhesiveness to the oral mucosa, can also slowly release drugs, and has relatively strong antibacterial performance; the repair and regeneration of oral mucosa epithelial tissues can be promoted. The gel can effectively act on the treatment process of oral diseases, is also suitable for daily oral care, and provides guarantee for oral health.

The present: invention relates to a pharmaceutical composition comprising curcumin and ginsenoside, and a formulation comprising same. Using curcumin and ginsenoids according to the present invention in combination with butyric acid and sucralfate restores cell growth, mobility, and endothelial cell tube-forming by ability reduced irradiation, and inhibits an inflammatory response induced in macrophages by LPS treatment. In addition, it was confirmed that, when an irradiated mouse is topically treated with the formulation according to the present invention comprising the compounds, intestinal epithelial tissue damaged by irradiation is restored and the expression of inflammatory cytokines in the intestinal tissue is suppressed. Furthermore, a mixture of a ginseng extract and a turmeric extract also restored the intestinal epithelial tissue damaged by irradiation. Therefore, the pharmaceutical composition comprising curcumin, ginsenoid, butyric acid, and sucralfate, or the pharmaceutical composition comprising a mixture of a ginseng extract and a turmeric extract, and the formulation according to the present invention comprising same can be utilized for treating radiation proctitis.

The invention belongs to the technical field of antibody preparation, and particularly relates to a monoclonal antibody aiming at human KRT19 and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and accurately target KRT19 in cytoplasm, has good affinity in combination with KRT19, has strong anti-interference ability, effectively ensures that a detection signal is from a target antigen, has a high conformity degree between a detection result and an actual situation, and has good application prospects. A powerful tool is provided for high-sensitivity and high-precision detection of the KRT19 in tissues and / or cells, deep research on functions and regulation mechanisms of the KRT19 in cytoskeleton, epithelial tissue and tumor biology is facilitated, and the kit has important application prospects.

To provide a composition for promoting tight junction formation that promotes formation of tight junctions between epithelial tissue cells.SOLUTION: A composition for promoting tight junction formation for promoting formation of tight junctions between epithelial tissue cells, contains triterpenes and skim milk and / or wheat gluten, thereby solving the problem to be solved.SELECTED DRAWING: None

The invention relates to a dental prosthesis element (1) comprising a body (4) provided with a micro-structured surface (14), and a coating (15) covering the micro-structured surface, the coating being intended to come into contact with an epithelial tissue (12) and / or a connective tissue (13), the coating comprising zirconium nitride.

The invention provides application of Mafb as a target spot in promotion of diabetic corneal epithelium injury repair, and belongs to the technical field of biological medicine. According to the application, the Mafb gene is taken as a treatment target, the repair speed of corneal epithelium injury can be obviously accelerated by over-expressing the Mafb gene in the cornea of a diabetic patient, and the expression levels of stem cell markers and cell proliferation markers in corneal epithelium tissues are obviously up-regulated. The invention also provides a recombinant adeno-associated virus AAV9-Mafb for overexpressing the Mafb gene, and the AAV9-Mafb can significantly recover the function of the corneal limbal stem cells of the diabetic mouse and promote the proliferation of corneal epithelial cells, thereby accelerating the repair of corneal epithelium injury of the diabetic mouse.

Methods of designing, generating, screening, and identifying one or more of these peptides possessing multiple functionalities, for example, including (i) high binding to a cellular target (e.g., melanin pigment in the eye), (ii) high cell-penetration (e.g., to enter cells and access melanin in the melanosomes), and (ii) low cytotoxicity have been developed. Peptides or drug conjugates thereof having these multiple functionalities are particularly effective for selective delivery, prolonged residence, and sustained release of active agents to the epithelial tissues via mucosal surfaces. Methods of using these peptides are also described.

The invention provides a bioactive citric acid-based polymer based on yeast oral delivery and a preparation method and application thereof, and the preparation method comprises the following steps: dissolving citric acid under the protection of inert gas, adding a hydroxyl-containing bridging agent and hydroxyl-containing natural bioactive small molecules, adding long-chain water-soluble hydroxyl-containing molecules at the same time, and stirring to obtain a mixed solution; and carrying out a melting reaction under a vacuum condition to obtain the PCGC prepolymer. The preparation method comprises the following steps: dispersing a PCGC prepolymer polymer and hyaluronic acid in a buffer solution, sequentially adding carbodiimide and N-hydroxysuccinimide to activate carboxyl, adding polyethyleneimine into an activation system to form PCGEA, mixing the treated yeast cell wall with the PCGEA, and carrying out self-deposition to obtain the PCGEA-YS. The polymer prepared by the invention can resist gastric acid erosion, efficiently target an inflammation part, relieve inflammation and promote intestinal epithelial tissue barrier repair, so that the polymer has a good application prospect in the aspects of treating inflammatory disease enteritis and promoting tissue repair.

The invention provides a human tonsil / adenoid epithelial cell culture method and a culture medium, and belongs to the technical field of biomedicine. The culture method comprises the following steps: separating epithelial tissues from in-vitro human tonsil / adenoid tissues; digesting epithelial tissues to obtain cell precipitates; lymphocytes are removed in a magnetic bead sorting mode, and primary human tonsil / adenoid epithelial cells are obtained through separation; carrying out amplification and differentiation culture by adopting a 3D cell culture medium, generating organoids at the upper part and generating adherent cells at the bottom; and carrying out enzymolysis on the adherent cells, and separating to obtain the human tonsil / adenoid epithelial cells. The culture method provided by the invention is relatively high in success rate and simple in steps, the human tonsil / adenoid epithelial cells obtained by culture are high in purity and can be continuously proliferated, and long-term in-vitro culture of the tonsil / adenoid epithelial cells is successfully realized.

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

The application relates to the technical field of cell culture, and particularly discloses a method for constructing an in-vitro layered culture model for observing the polarity of odontoblasts, which comprises the following steps: extracting mandibular incisor neck ring tissues, separating dental epithelial tissues and dental papilla tissues; separately digesting the dental epithelial tissues and the dental papilla tissues into single-cell suspensions; inoculating epithelial cells on the surface of movable polycaprolactone films for culture to obtain an epithelial cell-polycaprolactone film complex; carrying out adherent culture on dental papilla cells to proliferate, and pre-treating the dental papilla cells under experimental conditions during or after the culture; inoculating the pre-treated dental papilla cells in an upper chamber; adhering the epithelial cell-polycaprolactone film complex to a lower chamber; and removing the epithelial cell-polycaprolactone film complex. By adhering the epithelial cell-polycaprolactone film to the lower chamber for co-culture, the epithelial cells can induce the dental papilla cells to establish top-bottom polarity by relying on the gap of the chamber.

The invention relates to the technical field of cell culture, and particularly discloses an in-vitro layered culture model construction method for observing dentin cell polarity, and the method comprises the following steps: extracting mandibular incisor neck ring tissue, and separating odontogenic epithelial tissue from dental papilla tissue; respectively digesting the odontogenic epithelial tissue and the dental papilla tissue into single-cell suspensions; the method comprises the following steps: inoculating epithelial cells on the surface of a movable polycaprolactone membrane for culturing to obtain an epithelial cell-polycaprolactone membrane complex; performing adherent culture on the dental papilla cells for proliferation, and performing experimental condition pretreatment on the dental papilla cells in the culture process or after culture; inoculating the pretreated dental papilla cells into the upper chamber; the epithelial cell-polycaprolactone membrane complex is attached to a lower chamber; and the epithelial cell-polycaprolactone membrane complex is removed. Co-culture is realized by attaching an epithelial cell-polycaprolactone membrane to the lower part of the small chamber, and the epithelial cells can be utilized to induce dental papilla cells to establish top-bottom polarity by virtue of gaps of the small chamber.

The present invention relates to: an antigen-binding fragment of an anti-IL-4Rα antibody expressed in plant cells; and a composition for preventing or treating inflammation or autoimmune diseases comprising same as an active ingredient. The present invention provides an antigen-binding fragment of an anti-IL-4Rα antibody, specifically a scFv of dupilumab, expressed in plant cells, which exhibits binding affinity equal to or greater than dupilumab with respect to IL-4Rα while showing significantly increased epithelial cell permeability. Accordingly, the antigen-binding fragment of the present invention can be effectively used as an excellent anti-inflammatory pharmacological component which is locally administered to epithelial tissues, thereby minimizing a systemic effect on immune activity, concentrating a pharmacological effect on a lesion, and greatly improving patient administration convenience.

The invention relates to an application of dihydroergomine in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. A brand-new action mechanism is obtained through verification in an inflammatory bowel disease model, wherein TRIM25 can mediate ubiquitination degradation of LSD1 under the inflammatory condition, metabolic disorder of intestinal epithelial tissue is caused, and inflammation is aggravated. According to the application disclosed by the invention, by predicting structural information of combination of the TRIM25 and the LSD1, virtual medicine is used for screening, a dihydroergomine small molecule compound is screened, and the dihydroergomine small molecule compound can well occupy a combination site of interaction of the TRIM25 and the LSD1 and inhibit the interaction of the TRIM25 and the LSD1, so that degradation of the LSD1 is inhibited; in a DSS-induced mouse colitis model, the dihydroergomine can relieve inflammation activation caused by metabolic disorder of intestinal epithelium and well relieve symptoms of the inflammatory bowel disease. In the process, the action mechanism is clear, the effect is remarkable, new application of the dihydroergomine in the aspect of treating the inflammatory bowel disease is realized, and the dihydroergomine has higher clinical application value.

The application provides a method for establishing a Bactrian camel intestinal tract organoid model and application thereof, and the method is as follows: mucous mucus of Bactrian camel intestinal tract tissue is scraped off, washed, digested, washed again, crypt cells are scraped, cells are suspended in a culture medium, screened, filtrate is collected, centrifuged, supernatant is discarded, cells are resuspended in a DMEM / F12 culture medium containing bovine serum albumin to obtain a cell suspension; matrix glue is added to the cell suspension, mixed uniformly, inoculated, grown, grown culture medium is added, and then the Bactrian camel intestinal tract organoid model is obtained; and the obtained Bactrian camel intestinal tract organoid model is subcultured. The application also provides application of the Bactrian camel intestinal tract organoid model constructed by the construction method, which is used for in-vitro model construction of Bactrian camel intestinal tract related drugs or / and biological products. The construction method can efficiently obtain the Bactrian camel intestinal tract organoid which has self-organization and self-renewal capabilities and highly simulates intestinal epithelial tissue, and realizes stable subculture.

The present invention relates to a part (2) intended to be used in association with an implant (4) which is itself intended to be fixed in a jaw, this part comprising successively from its distal end (20) and in the direction of its proximal end (21), a distal portion (22) for fixing in the implant, an intermediate portion (23) for attachment to the epithelial and / or connective tissue and a proximal portion (24), this part also comprising at least two zones whose surfaces have a different structure, the structure of the surface of at least one of these two zones, located in said intermediate portion (23), called the first zone, being ordered and repetitive, adapted to the growth of the epithelial tissue and / or the connective tissue and having engravings forming undulations whose depth is less than 0.5 microns. Figure for the abstract: Fig. 2

The invention belongs to the technical field of primary cell culture, and particularly relates to a bronchial epithelial cell physiological or pathological model and a construction method and application thereof.The construction method comprises the steps that primary HBECs are provided, an amplification culture medium is used for conducting infiltration type amplification culture on the HBECs in a cell culture plug-in, after the cells form a complete barrier, the amplification culture medium is removed, and the model is obtained; carrying out gas-liquid interface culture on the cells in the cell culture plug-in by adopting a differential culture medium so as to induce the differentiation of the HBECs to form a false multi-layer columnar epithelial tissue structure; the cell culture plug-in comprises a porous membrane substrate, and construction of a physiological model or a pathological model is realized by selecting the cell culture plug-in of the porous membrane substrate with different pore diameters. According to the method, the in-vitro differentiation period of the HBECs can be remarkably shortened, and the model culture efficiency is greatly improved. The bronchial epithelium model capable of accelerating physiological differentiation or having pathological phenotype prepared by the method provided by the invention has significant advantages in drug screening and disease research.

The present invention relates to a method for producing a multi-tissue lung organoid structurally surrounded by fibroblasts, and a use thereof, and provides a three-dimensional structure composed of a lung organoid and a fibroblast layer surrounding the outside thereof. The organoid according to the present invention can maintain a high level of structural stability and bio-fidelity by reproducing a cell arrangement and microenvironment similar to those of actual lung tissue. The multi-tissue organoid more precisely reproduces a microenvironment in which epithelial tissues and interstitial tissues are arranged in layers as in a living body, rather than adopting a simple cell mixing method, and thus can be used in various biomedical applications, such as regenerative medicine, research on lung disease conditions, and evaluation of responsiveness to anticancer drugs and anti-fibrotic drugs. In addition, the present invention has excellent expandability to organoid-on-chip technology or bio-artificial organ development, and thus can be expected to be used as a precision medicine and next-generation cell therapy platform.

The present invention relates to a culture media system that useful for the isolation and epigenetically stable propagation of normal stem cells in culture which are derived from columnar epithelial tissues and cancer stem cells from epithelial cancers. In certain embodiments, the culture system is a feeder-free system.

Methods for non-invasive or minimally invasive assessment of epithelial tissue structure are disclosed. Digital imaging and processing are used to identify cell locations. More specifically, an automated algorithm that may be used to identify epithelial tissue structure, and / or to specify the coordinates / locations of cells in the epithelial tissue structure, through non-invasive or minimally invasive imaging, and use of this information to extract values of epithelial structure related parameters are disclosed.

The invention discloses an umbilical cord mesenchymal stem cell exosome targeting delivery system based on adenovirus-mediated EpCAM modification and application thereof, the system introduces an anti-EpCAM single-chain antibody gene into umbilical cord mesenchymal stem cells through an adenovirus vector, so that an anti-EpCAM single-chain antibody is stably expressed on the surface of exosome secreted by the umbilical cord mesenchymal stem cells; accurate targeting delivery of epithelial tissues is realized by using antigen-antibody specific binding, the problem of insufficient targeting of natural exosomes is effectively solved, and the exosome has remarkable advantages in epithelial tissue disease treatment and has good application prospects and important transformation significance.

The application discloses application of a hydrogel-coated human amniotic epithelial stem cell and exosomes thereof to preparation of a drug for improving intestinal inflammation, and intestinal inflammation symptoms of a mouse are significantly reduced through anal injection, which is manifested in faster recovery of body weight, lower disease activity score, and significant reduction of intestinal permeability increase caused by UC. Intestinal epithelial function reconstruction is promoted, which is manifested in intestinal permeability improvement, intestinal epithelial integrity improvement, inflammation reaction reduction, intestinal epithelial tissue regeneration promotion, and apoptosis reduction. According to the above results, the human amniotic epithelial stem cell and the exosomes thereof can be applied to UC treatment in combination with a biomaterial. The method has a wide prospect in clinical application of UC treatment.